Dr. Muhammad Tariq Khan (PhD RIU, Islamabad)

Assistant Professor

Dr. Khan has completed PhD. Degree in Pharmacy from Riphah International University (RIU), Islamabad, Pakistan, in 2021. Dr. Khan worked at different positions in pharmaceutical marketing and academia. Dr. Khan has broad research interests in the areas of pharmaceutical chemistry and medicinal chemistry. He authored several research papers in ISI-impact factor journals of national and international repute. He is the lifetime member of Punjab Pharmacy Council and Pakistan Pharmacist Association (PPA).

PhD Pharmacy Riphah International University, Islamabad 2021
MPhil Pharmaceutical Chemistry Bahauddin Zakariya University, Multan 2014
Pharm.D Pharmaceutical Sciences University of Sargodha, Sargodha 2011
Assistant Professor Capital University of Science and Technology (CUST), Islamabad Since – July 2021
Lecturer Capital University of Science and Technology (CUST), Islamabad October 2018 – June 2021
Assistant Professor Pakistan Margalla College of Pharmacy, Rawalpindi January 2018 – October 2018
Lecturer Mohi-ud-Din Islamic University, Mirpur September 2014 – January 2018
Product Manager UniMark Pharmaceuticals Ltd. February 2013 – September 2014
Product Specialist 3A Pharmaceuticals Ltd. February 2012 – July 2012
Medical Sales Executive GlaxoSmithKline Pvt. Ltd. 2011 – 2012
Member Punjab Pharmacy Council, Lahore, Pakistan
Member Pakistan Pharmacist Association
  1. Pharmaceutical chemistry, Organic synthesis, Pharmacological and toxicological evaluation of synthetic organic moieties, Drug Designing and Development, Virtual drug designing and in-silico screening.

1. A. Bukhari, H. Nadeem, S. Sarwar, I. Abbasi, M. T. Khan, I. Hamid, U. Bukhari. “Exploring Therapeutic Potential of 1,3,4-Oxadiazole Nucleus as Anticancer Agents: A Mini-Review.” Medicinal Chemistry, 2022.
2. A.M. Zubair, M.N.H. Malik, W. Younis, M.A.H. Malik, S. Jahan, I. Ahmed, A. Yuchi, M.N. Mushtaq, R. Tahir, M.B. Sarwar, and M. Roman. A. A. Khan, M. N Tahir, M. T. Khan, H. A. A, Kharl, G. Kamran, A.A Albegali1, A. Imran. “Novel acetamide derivatives of 2-aminobenzimidazole prevent inflammatory arthritis in rats via suppression of pro-inflammatory mediators.” Inflammopharmacology, vol. 16, pp.1-15, 2022.
3. A.Batool, G.A. Miana, M. Alam, M. T Khan, M. Muddassir, W. Zaman, Saifullah, A. Aman, A. Khusroo, M. V. Arasu, N.A. Al-Dhabi, K.C. Choi, and M. U. K. Shahibzada. “Bioassay-guided fractionation and isolation of Arctigenin from Saussurea heteromalla for in vitro and in silico cytotoxic activity against HeLa cells.” Physiological and Molecular Plant Pathology, 101749, 2021.
4. N.S. Malik, M. Ahmad, M.S. Alqahtani, A. Mahmood, K. Barkat, M.T. Khan, U.R. Tulain, and A. Rashid, “β-cyclodextrin chitosan-based hydrogels with tunable pH-responsive properties for controlled release of acyclovir: design, characterization, safety, and pharmacokinetic evaluation”, Drug Delivery, vol. 28, no. 1, pp. 1093-1108, 2021
5. M. T. Khan, H. Nadeem, A. S. Sheikh, N. S. Malik, M. Rizwan, M. Imran, I. Javed. A. Khan, and M. Abbas, “Amino acid derivatives of 2-Mercaptobenzimidazoles suppress cytokines at the site of inflammation and block gastric H/K ATPase”, Pakistan Journal of Pharmaceutical Sciences, vol. 34, no. 3, pp. 1157-1163, 2021
6. H. R. Afzal., N. U. H. Khan., K. Sultana., A. Mubashir., A. Lareb., A. Khan., M. T. Khan., and M. Imran, “Schiff bases of pioglitazone provide better antidiabetic and potent antioxidant effect in a streptozotocin–nicotinamide-induced diabetic rodent model”, ACS Omega, vol. 06, no. 06, pp. 4470-4479, 2021
7. M. T. Khan, H. Nadeem, A. U. Khan, M. Abbas, M. Arif, N.S. Shamshad, Z. Malik, and I. Javed, “Amino acid conjugates of 2-mercaptobenzimidazole provide better anti-inflammatory pharmacology and improved toxicity profile”, Drug Development Research, vol. 81, no. 08,pp. 1057-1072, 2020
8. A. M. Alvi, L. T. A. Kury, M. U. Ijaz, F. A. Shah, M. T. Khan, A. S. Sheikh, H. Nadeem, A. Khan, A. Zeb, and S. Li, “Post-treatment of synthetic polyphenolic 1,3,4 oxadiazole compound A3, attenuated ischemic stroke-induced neuroinflammation and neurodegeneration”, Biomolecules, vol. 10, no. 1, pp. 816, 2020
9. S. Iqbal, F. A. Shah, K. Naeem, H. Nadeem, S. Sarwar, Z. Ashraf, M. Imran, T. Khan, T. Anwar, and S. Li,“Succinamide derivatives ameliorate neuroinflammation and oxidative stress in scopolamine-induced neurodegeneration”, Biomolecules, vol. 10, no. 3, pp. 443, 2020
10. M. T. Khan, M. T. Razi, S. U. Jan, M. Mukhtiar, R. Gul, I. Ullah, A. Hussain, A. M. Hashmi, M. T. Ahmad, N. A. Shahwani, and I. Rabbani, “Synthesis characterization and antihypertensive activity of 2-Phenyl substituted benzimidazoles”, Pakistan Journal of Pharmaceutical Sciences, vol. 31, no.3, pp. 1067-1074, 2018
11. M. Hanif, H. U. Khan, S. Afzal, M. T. Khan, K. Afzal, and N. Iqbal, “Sustained release ivabradine lipospheres from camauba wax/stearic acid blend: formulation, evaluation, and optimization by central composite design”, Latin American Journal of Pharmacy, vol. 36, no. 1, pp. 25-36, 2017
12. H. Khan, A. Mahmood, S. Maheen, R. M. Sarfaraz, A. Youchi, A. Shameem, M. Akhtar, H. Ahsen, M. T. Khan, M. Khalil, and T. M. Rana, “Formulation and in vitro evaluation of novel antidiabetic orodispersible tablets using kyron-t134 and crosscaramellose sodium as superdisintegrants”, Latin American Journal of Pharmacy, vol. 33, no. 4, pp. 631-639, 2014
13. M. T. Razi, I. Javed, M. Z. Choudhary, M. T. Khan, and N. Mukhtar, “Effect of ketoprofen on lactic dehydrogenase from human platelets”, Advances in Clinical and Experimental Medicine, vol. 23, no. 3, pp. 377-380, 2013

Other Members